We first focused on PRMT5 because 1) PRMT5 was the top-scoring and druggable hit, 2) literature supports a role for PRMT5 in the progression of various cancer types, including breast cancer [24, 25], and 3) PRMT5 small molecule inhibitors (PRMT5i) are in clinical development, thus allowing us to test the antitumor effects of PRMT5 pharmacological inhibition. The gene discussed is PRMT5; the disease is breast carcinoma.